Switzerland-based Helsinn Group has signed an agreement with Danish firm Pharmacosmos for the exclusive commercialisation rights to Monofer in the US.
Monofer is an intravenous iron replacement therapy under development to treat iron deficiency anaemia.
Go deeper with GlobalData
Pharmacosmos CEO Lars Christensen said: “Helsinn’s strong foothold in the haematology and oncology combined with Pharmacosmos’ expertise on iron deficiency anaemia will provide an excellent platform for the introduction of Monofer in the US.”
Helsinn received exclusive rights to commercialise Monofer and any other iron isomaltoside 1000 products developed by Pharmacosmos in the US.
Under the deal, Pharmacosmos will secure payments of up to $130m for Monofer ?in iron deficiency anaemia in the US.
The company is also eligible to receive further payments for the manufacture and supply of Monofer? to Helsinn in the country.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataHelsinn Group CEO Riccardo Braglia said: “Helsinn is committed to improving the lives of patients by offering medicines which enable them to get the most out of every day, optimising their quality of life and promoting their ability to remain on treatment regimens.
“Monofer provides a high dose iron replacement in a single administration, which may offer anaemic patients a new, more convenient treatment option for rapidly restoring their iron stores and thereby, improve their symptom burden.”
Monofer (10% iron isomaltoside 1000) is an iron-carbohydrate complex for intravenous administration, and is currently marketed in 30 countries, primarily in Europe, to treat iron deficiency anaemia.
It is under development in other parts of the world, including North America and Japan.
Image: Blood smear of a patient with iron deficiency anaemia at 40x enhancement. Photo: courtesy of Roberto J Galindo.
